Johnson & Johnson $JNJ Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 84.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 495,161 shares of the company’s stock after selling 2,632,092 shares during the period. Pacer Advisors Inc.’s holdings in Johnson & Johnson were worth $91,813,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Lifestyle Asset Management Inc. lifted its holdings in Johnson & Johnson by 3.4% in the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock worth $312,000 after acquiring an additional 56 shares during the last quarter. Wynn Capital LLC raised its position in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock worth $2,954,000 after purchasing an additional 57 shares during the period. Defined Financial Planning LLC lifted its holdings in shares of Johnson & Johnson by 3.0% in the 3rd quarter. Defined Financial Planning LLC now owns 1,926 shares of the company’s stock worth $365,000 after purchasing an additional 57 shares during the last quarter. W.H. Cornerstone Investments Inc. boosted its position in Johnson & Johnson by 0.7% during the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after purchasing an additional 58 shares during the period. Finally, YANKCOM Partnership increased its position in Johnson & Johnson by 0.8% in the second quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after buying an additional 58 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.1%

JNJ stock opened at $207.54 on Friday. The firm’s 50-day moving average is $199.67 and its two-hundred day moving average is $181.03. The company has a market capitalization of $500.02 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. UBS Group boosted their price target on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Guggenheim boosted their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Argus set a $210.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a report on Monday, October 20th. Finally, The Goldman Sachs Group increased their price objective on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $210.25.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.